The FDA recently approved two new combination therapies for the treatment of HIV infection in adults. Both therapies are pharmacoenhanced protease inhibitors (PIs). Evotaz by Bristol-Myers Squibb is a combination of 300 mg atazanavir (Reyataz, Bristol-Myers Squibb) and 150 mg cobicistat (a pharmacokinetic enhancer by Gilead Sciences), which should be used with other antiretroviral agents. Evotaz should be dosed once a day. Read more bit.ly/1yga8lR
FDA Approves Two Combination Therapie... - HFI Connect - Hep...
HFI Connect - Hepatitis
920 members • 1,209 posts